Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Step Therapy For Medicare Part B Drugs Will Lower Costs By 20%, HHS Projects

Executive Summary

Beginning in 2019, Medicare Advantage plans may use step therapy in Part B, potentially including “cross management” with Part D drugs, under new guidance from the Centers for Medicare and Medicaid Services.

You may also be interested in...



UnitedHealthcare Coverage Policy Undercutting Neulasta Biosimilars Draws Concerns

US insurer’s commercial plans will favor the originator drug over biosimilars in return for a price concession from Amgen, while UnitedHealthcare’s Medicare Advantage plans will prefer biosimilars in several categories.

Humana Jumps In: Medicare Part B Step Therapy Program Includes Cancer Drugs

Biopharma manufacturers view implementation of management tool in Medicare Advantage plans with concern, urge US Centers for Medicare and Medicaid Services to withdraw permission for use of step therapy for Part B drugs. 

Part D Protected Class Management Tools To Save Medicare $1.85bn

CMS proposed rule would not eliminate any protected classes but would allow plans to impose additional restrictions on drugs in those classes. Proposal also codifies step therapy for Part B drugs.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS123651

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel